A phase 1 trial of Zelenectide pevedotin in multi-tumor patients
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Zelenectide pevedotin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms Duravelo-5
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to a Bicycle Therapeutics media release, company to initiate this trial in 2H 2025.